Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 11, 2024

Novel Azaspirooxindolinone-Based PROTACs for Selective BTK Degradation and Enhanced Anticancer Activity

View Full Paper
Ask AI
Bookmark
Share

Authors

NRNaveen Kumar RampeesaRGRambabu GundlaGMGopal Muddasani

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rampeesa et al. (2024) studied this question.

synapsesocial.com/papers/68e58dd5b6db6435875290cbhttps://doi.org/10.26434/chemrxiv-2024-pxdtn
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Novel Azaspirooxindolinone-Based PROTACs for Selective BTK Degradation and Enhanced Anticancer Activity2024 · 1 citations
  2. 2Optimization of Azaspirooxindolinone-based PROTACs targeting BTK: Synthesis, kinase profiling, and degradation analysis2026
  3. 3Discovery ofHighly Potent and Selective, Orally BioavailableBTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads2026
  4. 4Proteolysis-targeting chimera (PROTAC) targeting BTK degradation for cancer therapy in mantle cell lymphoma.2026
  5. 5Proteolysis-targeting chimera (PROTAC) to target Bruton tyrosine kinase (BTK) degradation in mantle cell lymphoma.2026